A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko Ko, Nway Le, Minaskeian, Nareg, El Masry, Hicham Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552504/
https://www.ncbi.nlm.nih.gov/pubmed/33062307
http://dx.doi.org/10.1186/s40959-020-00077-5
_version_ 1783593413864587264
author Ko Ko, Nway Le
Minaskeian, Nareg
El Masry, Hicham Z.
author_facet Ko Ko, Nway Le
Minaskeian, Nareg
El Masry, Hicham Z.
author_sort Ko Ko, Nway Le
collection PubMed
description This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.
format Online
Article
Text
id pubmed-7552504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75525042020-10-13 A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma Ko Ko, Nway Le Minaskeian, Nareg El Masry, Hicham Z. Cardiooncology Review This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen. BioMed Central 2020-10-13 /pmc/articles/PMC7552504/ /pubmed/33062307 http://dx.doi.org/10.1186/s40959-020-00077-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ko Ko, Nway Le
Minaskeian, Nareg
El Masry, Hicham Z.
A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title_full A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title_fullStr A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title_full_unstemmed A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title_short A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
title_sort case of irreversible bradycardia after rituximab therapy for diffuse large b-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552504/
https://www.ncbi.nlm.nih.gov/pubmed/33062307
http://dx.doi.org/10.1186/s40959-020-00077-5
work_keys_str_mv AT kokonwayle acaseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma
AT minaskeiannareg acaseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma
AT elmasryhichamz acaseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma
AT kokonwayle caseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma
AT minaskeiannareg caseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma
AT elmasryhichamz caseofirreversiblebradycardiaafterrituximabtherapyfordiffuselargebcelllymphoma

Ejemplares similares